|Bid||0.8773 x 600|
|Ask||0.8834 x 500|
|Day's Range||0.8658 - 0.8960|
|52 Week Range||0.8500 - 3.6500|
|PE Ratio (TTM)||-0.58|
|Earnings Date||Oct 30, 2017 - Nov 3, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||3.94|
Q2 2017 Regulus Therapeutics Inc Earnings Call
Regulus Therapeutics Inc. (RGLS) is a clinical stage biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field. Regulus is advancing several programs in renal, hepatic and central nervous systems diseases. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements.
The San Diego-based company said it had a loss of 41 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...